The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
Open accessAbstract
We developed, synthesized, and tested a multifunctional nanostructured lipid nanocarrier-based system (NLCS) for efficient delivery of an anticancer drug and siRNA directly into the lungs by inhalation. The system contains: (1) nanostructured lipid carriers (NLC); (2) anticancer drug (doxorubicin or paclitaxel); (3) siRNA targeted to MRP1 mRNA as a suppressor of pump drug resistance; (4) siRNA targeted to BCL2 mRNA as a suppressor of nonpump cellular resistance and (5) a modified synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific to the receptors that are overexpressed in the plasma membrane of lung cancer cells. The NLCS was tested in vitro using human lung cancer cells and in vivo utilizing mouse orthotopic model of human lung cancer. After inhalation, the proposed NLCS effectively delivered its payload into lung cancer cells leaving healthy lung tissues intact and also significantly decreasing the exposure of healthy organs when compared with intravenous injection. The NLCS showed enhanced antitumor activity when compared with intravenous treatment. The data obtained demonstrated high efficiency of proposed NLCS for tumor-targeted local delivery by inhalation of anticancer drugs and mixture of siRNAs specifically to lung cancer cells and, as a result, efficient suppression of tumor growth and prevention of adverse side effects on healthy organs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K., & Gewirtz, D. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10149-1 · Cited by 436
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.
Momparler, R. L., Karon, M. R., Siegel, S. E., & Avila, F. (1976) · PubMed · Cited by 423
Mechanisms and strategies to overcome multiple drug resistance in cancer
Ozben, T. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.020 · Cited by 406
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Self-citationTumor-specific targeting of an anticancer drug delivery system by LHRH peptide
Dharap, S. S., Wang, Y., Chandna, P., Khandare, J. J., Qiu, B., Gunaseelan, S., Sinko, P. J., Stein, S., Farmanfarmaian, A., & Minko, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504274102 · Cited by 340
Self-citationTaratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H., & Minko, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.019 · Cited by 328
Self-citationTaratula, O., Garbuzenko, O. B., Chen, A. M., & Minko, T. (2011) · Journal of Drug Targeting · doi:10.3109/1061186x.2011.622404 · Cited by 245
Self-citationSaad, M., Garbuzenko, O. B., Ber, E., Chandna, P., Khandare, J. J., Pozharov, V. P., & Minko, T. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.024 · Cited by 238
Self-citationSurface-Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery
Patil, M. L., Zhang, M., Betigeri, S., Taratula, O., He, H., & Minko, T. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8000722 · Cited by 213
Self-citationHUANG, Z.-R., HUA, S.-C., YANG, Y.-L., & FANG, J.-Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00829.x · Cited by 200
Minko, T., Kope?kov�, P., & Kope?ek, J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<108::aid-ijc17>3.0.co;2-8 · Cited by 198
Self-citationA controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers
Li, X., Nie, S.-F., Kong, J., Li, N., Ju, C.-Y., & Pan, W.-S. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.017 · Cited by 195
Garbuzenko, O. B., Saad, M., Pozharov, V. P., Reuhl, K. R., Mainelis, G., & Minko, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004604107 · Cited by 185
Self-citationMolecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
Dharap, S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00209-8 · Cited by 172
Garbuzenko, O. B., Saad, M., Betigeri, S., Zhang, M., Vetcher, A. A., Soldatenkov, V. A., Reimer, D. C., Pozharov, V. P., & Minko, T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9755-4 · Cited by 167
Self-citationTaratula, O., Garbuzenko, O. B., Savla, R., Wang, Y. A., He, H., & Minko, T. (2010) · Current Drug Delivery · doi:10.2174/156720111793663642 · Cited by 154
Self-citationPakunlu, R. I., Wang, Y., Tsao, W., Pozharov, V. P., Cook, T. J., & Minko, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0001 · Cited by 148
Self-citationPakunlu, R. I., Wang, Y., Saad, M., Khandare, J. J., Starovoytov, V., & Minko, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.010 · Cited by 134
Self-citationThe pharmacology of cancer resistance.
O'Connor, R. A. (2007) · PubMed · Cited by 123
RNA interference: The molecular immune system
Bagasra, O., & Prilliman, K. R. (2004) · The Histochemical Journal · doi:10.1007/s10735-004-2192-8 · Cited by 123
Pakunlu, R. I., Cook, T. J., & Minko, T. (2003) · Pharmaceutical Research · doi:10.1023/a:1022687617318 · Cited by 109
Self-citationRecent advances of novel targeted therapy in non-small cell lung cancer
Katzel, J. A., Fanucchi, M. P., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-2 · Cited by 88
Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy
Khandare, J. J., Chandna, P., Wang, Y., Pozharov, V. P., & Minko, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098855 · Cited by 83
Self-citationTargeted Proapoptotic Anticancer Drug Delivery System
Chandna, P., Saad, M., Wang, Y., Ber, E., Khandare, J. J., Vetcher, A. A., Soldatenkov, V. A., & Minko, T. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070053o · Cited by 69
Self-citationThe current status of targeted therapy for non‐small cell lung cancer
Francis, H., & Solomon, B. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02141.x · Cited by 66
Wang, Y., Saad, M., Pakunlu, R. I., Khandare, J. J., Garbuzenko, O. B., Vetcher, A. A., Soldatenkov, V. A., Pozharov, V. P., & Minko, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2020 · Cited by 57
Self-citationChandna, P., Khandare, J. J., Ber, E., Rodrı́guez-Rodrı́guez, L., & Minko, T. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0235-2 · Cited by 53
Self-citationZhang, M., Garbuzenko, O. B., Reuhl, K. R., Rodríguez-Rodríguez, L., & Minko, T. (2012) · Nanomedicine · doi:10.2217/nnm.11.131 · Cited by 52
Self-citationChemotherapy for lung cancer: the state of the art in 2009
Higgins, M. J., & Ettinger, D. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.115 · Cited by 50
Formulations for Pulmonary Administration of Anticancer Agents to Treat Lung Malignancies
Carvalho, T. C., Carvalho, S. R., & McConville, J. T. (2011) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0794 · Cited by 47
Amaral, L., Engi, H., Viveiros, M., & Molnar, J. A. (2007) · PubMed · Cited by 44
Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms
Carbone, D. P., & Felip, E. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.002 · Cited by 36
Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Merino, V., Jiménez-Torres, N. V., & Merino‐Sanjuán, M. (2004) · Current Drug Delivery · doi:10.2174/1567201043334650 · Cited by 26
Targeted Delivery of Nucleic Acid-Based Therapeutics to the Pulmonary Circulation
Kuruba, R., Wilson, A. S., Gao, X., & Li, S. (2009) · The AAPS Journal · doi:10.1208/s12248-008-9073-0 · Cited by 20
Betigeri, S., Zhang, M., Garbuzenko, O. B., & Minko, T. (2010) · Drug Delivery and Translational Research · doi:10.1007/s13346-010-0003-1 · Cited by 19
Self-citation
Cited by
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 619
Metadata
- Authors
- Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 171
- Issue
- 3
- Pages
- 349-357
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2105395122
- Cited by
- 416
- References
- 36
- FWCI
- 26.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.